Dianthus Therapeutics (DNTH) Stock Statistics & Valuation Metrics

Dianthus Therapeutics has a market cap or net worth of $4.80B. The enterprise value is $4.21B.

Market Cap

$4.80B

Enterprise Value

$4.21B

Dianthus Therapeutics has 55,934,380 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

55,934,380

Owned by Insiders

0.15%

Owned by Institutions

54.87%

Dianthus Therapeutics’s return on equity (ROE) is -0.33 and return on invested capital (ROIC) is -35.55%.

Return on Equity (ROE)

-0.33

Return on Assets (ROA)

-0.31

Return on Invested Capital (ROIC)

-35.55%

Return on Capital Employed (ROCE)

-0.36

Revenue Per Employee

22.13K

Profits Per Employee

-1.76M

Employee Count

92

Asset Turnover

0.00

Inventory Turnover

0.00

The current PE Ratio of Dianthus Therapeutics is 2767.00. Dianthus Therapeutics’s PEG ratio is 22.04.

PE Ratio

2767.00

PS Ratio

1708.28

PB Ratio

3.83

Price to FCF

-26.40

Price to Operating Cash Flow

-27.18

PEG Ratio

22.04

In the last 12 months, Dianthus Therapeutics had revenue of 2.04M and earned -162.34M in profits. Earnings per share was -4.20.

Revenue

2.04M

Gross Profit

2.04M

Operating Income

-177.93M

Pretax Income

-162.34M

Net Income

-162.34M

EBITDA

-161.91M

Earnings Per Share (EPS)

-4.20

In the last 12 months, operating cash flow was -175.15M and capital expenditures -697,000, giving a free cash flow of -175.85M billion.

Operating Cash Flow

-175.15M

Free Cash Flow

-175.85M

Free Cash Flow per Share

-3.07

Dianthus Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-3.78%

Earnings Yield

-0.83%

Beta

0.85

52-Week Price Change

146.10%

50-Day Moving Average

91.56

200-Day Moving Average

86.09

Relative Strength Index (RSI)

48.49

Average Volume (3m)

842.55K

Dianthus Therapeutics upcoming earnings date is Mar 16, 2027, TBA (Not Confirmed).

Last Earnings Date

Nov 04, 2026

Next Earnings Date

Mar 16, 2027

Ex-Dividend Date

―

Dianthus Therapeutics as a current ratio of 13.32, with Debt / Equity ratio of 0.28%

Current Ratio

13.32

Quick Ratio

13.32

Debt to Market Cap

0.00

Net Debt to EBITDA

0.31

Interest Coverage Ratio

0.00

In the past 12 months, Dianthus Therapeutics has paid 0 in taxes.

Income Tax

0

Effective Tax Rate

0.00

Dianthus Therapeutics EV to EBITDA ratio is -116.78, with an EV/FCF ratio of -26.16.

EV to Sales

1692.77

EV to EBITDA

-116.78

EV to Free Cash Flow

-26.16

EV to Operating Cash Flow

-26.27

Dianthus Therapeutics has $837.78M in cash and marketable securities with $1.21M in debt, giving a net cash position of $836.58M billion.

Cash & Marketable Securities

$837.78M

Total Debt

$1.21M

Net Cash

$836.58M

Net Cash Per Share

$14.96

Tangible Book Value Per Share

$21.65

Gross margin is 97.20%, with operating margin of -8683.89%, and net profit margin of -1463.83%.

Gross Margin

97.20%

Operating Margin

-8683.89%

Pretax Margin

-1463.83%

Net Profit Margin

-1463.83%

EBITDA Margin

-1449.52%

EBIT Margin

-1463.83%

The average price target for Dianthus Therapeutics is $134.56, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

$134.56

Price Target Upside

62.10% Upside

Analyst Consensus

Strong Buy

Analyst Count

10

Revenue Growth Forecast

-11.70%

EPS Growth Forecast

-14.33%

Smart Score

3

AI Score

51